The term inflammation from the Latin word flamma for fire, was intended to cover the most complex manifestations of the phenomenon.

Inflammation is an evolutionarily conserved process characterized by the activation of innate and adaptive immunity that protect the host from virus and bacteria.

Today, chronic inflammation has been recognized as the most significant cause of death in the world, with more than 50% of all deaths being attributable to inflammation-mediated diseases.

Immetas discovers and develops novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases. The company’s approach is based on emerging evidence that chronic low-grade inflammation is a fundamental process governing aging and age-related diseases.